Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
CA 2433762 A1 · Owner: Pharmacia Italia S.P.A. · Inventors: Granata, Francesco; Pamparana, Franco; Stragliotto, Eduardo Lino
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns a method of therapeutic prevention and treatment of a heart disease chosen from cardiac insufficiency and heart failure including the administration of an essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), either alone or in combination with another therapeutic agent.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.